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The highly homologous human leukocyte antigen (HLA)-DQ2
molecules, HLA-DQ2.5 and HLA-DQ2.2, are implicated in the
pathogenesis of celiac disease (CeD) by presenting gluten peptides
to CD4+ T cells. However, while HLA-DQ2.5 is strongly associated
with disease, HLA-DQ2.2 is not, and the molecular basis underpin-
ning this differential disease association is unresolved. We here
provide structural evidence for how the single polymorphic resi-
due (HLA-DQ2.5-Tyr22α and HLA-DQ2.2-Phe22α) accounts for HLA-
DQ2.2 additionally requiring gluten epitopes possessing a serine
at the P3 position of the peptide. In marked contrast to the biased
T cell receptor (TCR) usage associated with HLA-DQ2.5–mediated
CeD, we demonstrate with extensive single-cell sequencing that a
diverse TCR repertoire enables recognition of the immunodomi-
nant HLA-DQ2.2-glut-L1 epitope. The crystal structure of two
CeD patient-derived TCR in complex with HLA-DQ2.2 and DQ2.2-
glut-L1 (PFSEQEQPV) revealed a docking strategy, and associated
interatomic contacts, which was notably distinct from the struc-
tures of the TCR:HLA-DQ2.5:gliadin epitope complexes. Accord-
ingly, while the molecular surfaces of the antigen-binding clefts
of HLA-DQ2.5 and HLA-DQ2.2 are very similar, differences in the
nature of the peptides presented translates to differences in
responding T cell repertoires and the nature of engagement of
the respective antigen-presenting molecules, which ultimately is
associated with differing disease penetrance.
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Celiac disease (CeD) is a heritable and chronic inflammatorydisorder that is caused by a maladaptive immune response to
cereal gluten proteins (1). While exhibiting features of food in-
tolerance, the disease also has many autoimmune characteristics
including highly disease-specific autoantibodies targeting the
enzyme transglutaminase 2 (TG2). CeD patients, but not healthy
subjects, have gluten-specific CD4+ T cells (2). These T cells,
persisting for decades in patients (3), are considered drivers
of the CeD pathophysiology that includes the formation of an
inflammatory lesion in the proximal small intestine and the gen-
eration of autoantibodies (4). The gluten-specific T cells are
uniquely restricted by disease-associated HLA-DQ allotypes, namely
HLA-DQ2.5 (HLA-DQA1*05/HLA-DQB1*02:01), HLA-DQ2.2
(HLA-DQA1*02:01/HLA-DQB1*02:02), and HLA-DQ8 (HLA-
DQA1*03:01/HLA-DQB1*03:02) (5–7). About 90% of patients
affected by CeD are HLA-DQ2.5 positive, and those who do not
carry HLA-DQ2.5 are equally often either HLA-DQ2.2 or HLA-
DQ8. Interestingly, while the risk of the three disease-associated
HLA-DQ allotypes are very different, the clinical presentations of
patients with the different HLA-DQ allotypes are the same (7).
This suggests that the differential risks relate to likelihood of
generating an anti-gluten T cell response, and once the gluten-
specific T cells are established and clonally expanded, exposure to
gluten leads to the same pathophysiological reactions.
The gluten peptides recognized by T cells of CeD patients are
posttranslationally modified. TG2 is essential in this process as
the enzyme can convert glutamine residues in polypeptides to
glutamate, mostly following a QXP recognition motif (8, 9).
Gluten proteins are exceptionally rich in such sequence motifs but
naturally sparse in negatively charged residues that is required for
a high-affinity binding to peptide-binding pockets within the
antigen-binding cleft of the disease-associated HLA-DQ allotypes
(7). The TG2-mediated deamidation of gluten peptides leads to
an increase in binding affinity and the formation of kineti-
cally stable peptide–HLA-DQ complexes (10). Hence, this post-
translational modification is essential for the immunogenicity
of these antigens (11–13), and the immune reactions inflicting
damage that ensue T cell recognition of HLA-DQ gluten peptide
complexes is likely the mechanism behind the absolute association
of certain HLA-DQ allomorphs with CeD (7). Generally, T cell
clones restricted by the three CeD-associated HLA allotypes
recognize distinct and separate sets of gluten epitopes (4, 14, 15).
This selectivity is based on the capacity of peptides to form ki-
netically stable peptide–HLA-DQ complexes as only peptides that
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form stable peptide complexes can elicit T cell clonal expansions
in vivo (14, 16).
While HLA-DQ8 binds and presents gluten peptides with
glutamate at anchor positions P1 and/or P9 (15, 17, 18), HLA-
DQ2.5 and HLA-DQ2.2 binds and presents gluten peptides with
glutamate residues at anchor positions P4, P6, or P7 (15, 19–23).
Three known HLA-DQ2.2–restricted epitopes, namely DQ2.2-
glut-L1 (PFSEQEQPV), DQ2.2-glia-α1 (QGSVQPQQL), and
DQ2.2-glia-α2 (QYSQPEQPI), have sequences similar to HLA-
DQ2.5–binding peptides, with the exception that they all carry
serine at P3 (14, 24, 25). As seen for HLA-DQ2.5–restricted
epitopes, the HLA-DQ2.2–restricted epitopes display a hierar-
chy with DQ2.2-glut-L1 being the epitope recognized by most
T cells (24). In binding experiments with DQ2.2-glut-L1 variant
peptides substituted at P3, HLA-DQ2.2 but not HLA-DQ2.5
showed preferential binding of the serine and threonine variants
(14). An earlier study had indicated that HLA-DQ2.2, in con-
trast to HLA-DQ2.5, utilizes a P3 anchor (20), and a P3 anchor
selectivity of HLA-DQ2.2 for serine or threonine was demon-
strated when comparing the repertoires of endogenous peptide
ligands eluted from purified HLA-DQ2.5, HLA-DQ2.2, and HLA-
DQ7.5 molecules (25).
The HLA-DQ2 molecules, HLA-DQ2.5 and HLA-DQ2.2, are
highly homologous. Previous studies have ascribed the differ-
ences in conferred risk associated with CeD as a result of the
polymorphism in the DQα chain between HLA-DQ2.5 and
HLA-DQ2.2 (14, 16). In particular, the Tyr22α to Phe22α
polymorphism is located near the P3 peptide binding pockets of
the HLA-DQ molecule. Here, we examined the role of Phe22α
variant in HLA-DQ2.2 that influence peptide binding preferences
and how the T cell receptors (TCRs) derived from DQ2.2 CeD
patients engage the HLA-DQ2.2:DQ2.2-glut-L1 complex. We
provide a molecular basis for these key interactions in HLA-
DQ2.2–mediated CeD and demonstrate how this is different
from HLA-DQ2.5– and HLA-DQ8–mediated epitope presentation
and TCR recognition in CeD.
Results
DQ2.2-glut-L1–Specific TCR Repertoire. We performed high-
throughput DNA sequencing of rearranged TRAV and TRBV
genes of the single HLA-DQ2.2:DQ2.2-glut-L1 tetramer binding
CD4+ T cells isolated from six T cell lines (TCLs) of four CeD
patients described in a previous study (14), specifically CD555
(TCL555.A.1.4 and TCL555.A.2.2), CD594 (TCL594.5.2 and
TCL594.8.1), CD627 (TCL627.7.3), and CD1005 (TCL1005.1).
Following processing of sequencing data, we obtained productive
paired TCRαβ sequences of 549 cells that were categorized into
18 unique clonotypes (Table 1). Cells expressing paired identical
nucleotide TRAV/TRBV genes are defined as a clonotype. We
also obtained five unique clonotypes by sequencing TRAV/TRBV
gene sequences of the T cell clones generated from the same four
patients. Of those five unique clonotypes, cells expressing the
same TCR as that of three unique T cell clones were observed as
clonally expanded population in the single-cell sequencing data
generated by tetramer-based sorting. In total, we generated 20
unique clonotypes of DQ2.2-glut-L1–specific T cells from
tetramer-sorted single cells and DQ2.2-glut-L1–specific T cell
clones.
We observed that few clonotypes dominate the DQ2.2-glut-L1–
specific TCR repertoire in the TCLs derived from HLA-DQ2.2–
positive CeD patients. In the majority of the patients, one or two
expanded clonotypes dominated the T cell repertoire. However, we
cannot exclude that some of this bias is the effect of in vitro culture
of the TCLs. As the number of unique DQ2.2-glut-L1–specific
TCRs is small and the dataset is obtained from TCLs generated by
in vitro culture, caution should be exercised on generalizing features
of the DQ2.2-glut-L1–specific TCR repertoire. In our fairly lim-
ited dataset, we observed that while some V genes like TRAV21,
TRAV26-1, TRBV20-1, and TRBV7-2/3 genes were expressed in
more than one CeD patient, there was no apparent V gene bias,
preferential TRAV:TRBV pairing or conserved CDR3 features
in DQ2.2-glut-L1–specific TCR repertoire. In two patients
(CD1005, CD555), we observed T cells expressing TCRs with
identical CDR3α and CDR3β amino acid sequences. The CDR3
of these public TCRs are encoded by different nucleotides, rep-
resenting a phenomenon termed convergent recombination (26).
Among these HLA-DQ2.2:DQ2.2-glut-L1–specific T cell
clones, four TCRs were expressed and successfully refolded:
TCR 555 (TRAV1-1*01/TRBV6-2*01), TCR 594 (TRAV9-2*01/
TRBV11-2*01), TCR 627 (TRAV3*01/TRBV28*01), and TCR
1005.2.56 (TRAV21*02/TRBV7-3*01) (Table 1 and SI Appendix,
Table S1). These four HLA-DQ2.2-glut-L1 reactive TCRs do
not contain a conserved arginine residue in the CDR loops that
underpin the response to gluten antigens in HLA-DQ2.5:DQ2.5-
glia-α2, HLA-DQ8:DQ8-glia-α1, and HLA-DQ8:DQ8.5-glia-γ1
reactive TCRs and displayed more diverse TRAV/TRBV gene
usage (22).
Structural Overview of Two TCR:HLA-DQ2.2:DQ2.2-glut-L1 Complexes.
To establish how TCRs interacts with HLA-DQ2.2:DQ2.2-glut-L1,
we determined the structure of the TCR 594:HLA-DQ2.2:DQ2.2-
glut-L1 and TCR 1005.2.56:HLA-DQ2.2:DQ2.2-glut-L1 ternary
complexes at 2.8 Å and 3.0 Å resolution, respectively (Fig. 1 and SI
Appendix, Table S2). The TCR 594 docked centrally above HLA-
DQ2.2:DQ2.2-glut-L1, ∼85° across the antigen-binding cleft, where
the Vα and Vβ chains of the TCR lay above the β-helix and α-helix
of HLA-DQ2.2, respectively (Fig. 1 A and C). The total buried
surface area (BSA) upon ligation of TCR 594 with HLA-
DQ2.2:DQ2.2-glut-L1 was ∼1,900 Å2. The Vα and Vβ domains of
the TCR 594 contributed 45.4% and 54.6%, respectively, to the
BSA at the interface (Fig. 1C). Notably 36.5% BSA arose from the
CDR3β loop, which played a dominant role in contacting the epi-
tope and HLA-DQ2.2 (Fig. 1C). There was a relatively even dis-
tribution of contacts among the CDR loops toward the HLA-DQ2.2
molecule, with the CDR1α, CDR2α, CDR3α, and CDR2β loops,
contributing 16.4%, 13.6%, 11.2%, and 14.1% BSA to the interface,
respectively.
The TCR 594 α-chain interacted with the HLA-DQ2.2
β-chain, spanning from Asp66β to Arg80β (Fig. 2A and SI Ap-
pendix, Table S3). Here, Tyr30α from the CDR1α loop made van
der Waals (vdw) contacts with Asp76β and Arg80β of HLA-
DQ2.2, while Thr57α and Asn58α from the CDR2α loop made
vdw contacts with Glu69β, Arg72β, and Ala73β (Fig. 2A). The
neighboring Vα framework residue Lys55α further stabilizes the
CDR2α–HLA-DQ2.2 interactions by forming a salt bridge with
Asp66β and Glu69β. Regarding the TCR β-chain, the CDR2β
loop made the majority of the contacts with the HLA-DQ2.2
α-chain (Fig. 2B). Namely, multiple vdw contacts between
Gln57β, Asn58β, and Gly64β from the TCR and the HLA-DQ2.2
residues Lys39α, Gln57α, and Thr61α were observed. Moreover,
additional vdw contacts were made between the Vβ framework
residue Val66β and the HLA-DQ2.2 residue Asp55α (Fig. 2B).
Accordingly, the TCR 594 engaged the HLA-DQ2.2 molecule in a
standard docking mode, with varied contributions from each of
the germ-line–encoded CDR loops.
The TCR 1005.2.56 also adopted a canonical docking position
at ∼60° across the antigen-binding cleft (Fig. 1 B and D). The
total BSA upon ligation of TCR 1005.2.56 with HLA-
DQ2.2:DQ2.2-glut-L1 was slightly higher than TCR 594 with
∼2,030 Å2, where the contribution of the Vα and Vβ domains of
the TCR 1005.2.56 to the BSA at the interface were 43.8% and
56.2%, respectively. The TCR 1005.2.56 CDR loops made rel-
atively even contact across the HLA-DQ2.2:DQ2.2-glut-L1
(Figs. 1D and 3). However, the TCR 1005.2.56 made contact
with the DQ2.2-glut-L1 epitope with both germ-line–encoded
CDR1α and nongerm-line–encoded CDR3β loop (Figs. 1D and
3064 | www.pnas.org/cgi/doi/10.1073/pnas.1914308117 Ting et al.
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3D), rather than just the CDR3 residues as seen in the TCR594
ternary complex.
Compared to the TCR 594, the CDR1α loop of the TCR
1005.2.56 shifted closer to the peptide antigen (SI Appendix, Fig.
S2A), where Tyr37α made contacts with Phe58α and Arg77β
from HLA-DQ2.2-glut-L1, as well as forming a hydrogen bond
with the main chain of the peptide P3-Ser and vdw interactions
with the P2-Phe (Fig. 3 A and D and SI Appendix, Tables S4 and
S5). This further allows the CDR3α loop to make vdw contact
with the Asp55α and Phe58α from HLA-DQ2.2 (Fig. 3A). The
CDR2α loop of the TCR 1005.2.56 made similar contacts with
the Glu69β, Arg70β, and Ala73β from HLA-DQ2.2 through vdw
interactions (Fig. 3A), comparable to the TCR 594 interactions
(Fig. 2A). All three CDRβ loops from the TCR 1005.2.56 also
interacted with the HLA-DQ2.2 molecule (Fig. 3 B and C).
Similar vdw contacts between CDR1β and CDR2β with a stretch
of the helix of the HLA-DQ2.2 α-chain were observed (Fig. 3B).
The Vβ framework residue Tyr55β, Ala66β, and Asp67β further
supported the interactions between CDR1β and CDR2β and the
HLA-DQ2.2 by making hydrogen bond with HLA-DQ2.2 resi-
due Gln57α and additional vdw contacts with Thr61α, Ala64α,
and His68α (Fig. 3B). The TCR 1005.2.56 CDR3β also made
extensive hydrogen bonds with the HLA-DQ2.2 β-chain (Fig.
3C). Overall, all CDR loops from both Vα and Vβ domains
of the TCR 1005.2.56 made a fairly even number of contacts
with both the HLA-DQ2.2 as well as the DQ2.2-glut-L1 epitope
(Fig. 3E).
DQ2.2-glut-L1 Peptide-Mediated TCR Interactions. The DQ2.2-glut-
L1 epitope residues that were exposed for TCR contact were P2-
Phe, P5-Gln, and P7-Gln (Fig. 2C and SI Appendix, Table S5).
The nongerm-line–encoded CDR3 loops of the TCR 594 con-
tacted all three positions, contributing to 22% BSA of the pep-
tide HLA interface (SI Appendix, Table S5). Here, the CDR3α
loop made limited contact, interacting only with the P2-Phe in
the DQ2.2-glut-L1 peptide (Fig. 2C). However, there was an
intricate network of polar interactions between the Glu112α
residue of CDR3α loop, Arg70β of the HLA-DQ2.2, and the P5-
Gln in the DQ2.2-glut-L1 peptide (Fig. 2D). This P5-Gln of the
DQ2.2-glut-L1 peptide also formed a hydrogen bond with Gly109β
of the CDR3β loop, and all together, appeared as a focal point for
the CDR3 α/β-loops of the TCR 594 on to the HLA-DQ2.2:DQ2.2-
glut-L1 (Fig. 2D).
The TCR 594 interacted with P7-Gln mostly via its CDR3β
loop (Fig. 2C and SI Appendix, Table S5). The small glycine
residues in the CDR3β loop, namely Gly109β, Gly110β, and
Gly112β which flanked the Trp111β, permitted close contact with
the peptide and formed hydrogen bond with the side chain of P5-
Gln and P7-Gln (Fig. 2 C and D). The CDR3β loop of the TCR
594 also displayed extensive interactions with the surrounding
residues, where Trp111β formed a hydrogen bond with the side
Table 1. DQ2.2-specific TCR sequences
No. Donor TRAV TRAJ CDR3a TRBV TRBD TRBJ CDR3b
No.
of cells TCC
1 1005 12-3 34 CAMTLNTDKLIF 4-2 1 1-2 CASSLQGGDYGYTF 1
2 1005 38-1*01 32*02 CAFMKEDGGATNKLIF 20-1*01 1*02 2-5*01 CSASPGNTGVAQYF 5 1005.2.54
and 1005.2.60
3 1005 26-1 48 CIVYLSNFGNEKLTF 5-5 2 2-2 CASSLIGGGELFF 1 —
4 1005 29/DV5 42 CAASAHYGGSQGNLIF 12-5 1 1-1 CASGPGTATEAFF 1 —
5 1005 38-2/DV8 58 CAYRSQETSGSRLTF 20-1 1 2-5 CSASWLGFGETQYF 9 —
6 1005 38-2/DV8 58 CAYTPLETSGSRLTF 20-1 1 2-7 CSARAPITGRFYEQYF 4 —
7 1005 21 42 CAVRPGGSQGNLIF 4-2 2 2-5 CASSLTTSEETQYF 74 —
29/DV5 30 CAASADLTNRDDKIIF
8 1005 38-1 42 CAFMKGSYGGSQGNLIF 7-8 1 2-7 CASSRTANYEQYF 28 —
40 40 FLLGITSGTYKYIF
9 1005 26-1 54 CIVRVAEGAQKLVF 20-1 2-5 CSATKETQYF 1 —
10 1005 26-1 54 CIVRVAEGAQKLVF 20-1 1 2-5 CSATKETQYF 3 —
11 1005 21*02 31*01 CAVHTGARLMF 7-3*01 1*01 2-3*01 CASSHGASTDTQYF NA 1005.2.56, 1005.2.57,
1005.2.58, 1005.2.62,
and 1005.2.65
12 555 26-1 54 CIVRVAEGAQKLVF 20-1 — 2-5 CSATKETQYF 3 —
13 555 6 26 CALVRDYGQNFVF 7-2 2 2-7 CASSTSGGGARSYEQYF 1 —
14 555 1-1*01 9*01 CAWTGGGGFKTIF 6-2*01 2*01 2-7*01 CASRKPGGDYEQYF 80 555A.1.4.38
15 555 21 58 CAVIGTSGSRLTF 7-3 1 2-3 CASSSGAATDTQYF 166 —
16 594 26-1 54 CIVRPAQGAQKLVF 29-1 2 1-2 CSVSSGGEGGNGYTF 1 —
17 594 9-2*01 57*01 CASPQGGSEKLVF 11-2*01 1*01 1-1*01 CASSSGGWGGGTEAFF 62 594.5.2.6†
27 21 CAGRDDFNKFYF
18 627 6 39 CALGLNNNAGNMLTF 10-3 1 2-5 CAISPRQAETQYF 1 —
19 627 21 11 CAASGYSTLTF 11-1 1 2-3 CASTHGAGSDTQYF 108 —
20 627 3*01 8*01 CAVSGNTGFQKLVF 28*01 2*02 1-5*01 CASTSRGGNSNQPQHF NA 627.1.3.199
DV1*01 12*01 CALGATVMDSSYKLIF
The table shows the total overview of unique TCRαβ paired sequences generated from high-throughput sequencing of HLA-DQ2.2:DQ2.2-glut-L1
tetramer-sorted single T cells and/or by Sanger sequencing of DQ2.2-glut-L1–specific TCCs. Due to uncertainty in the allele assignment in the TCRαβ
sequences generated from single-cell TCR sequencing approach, the alleles for the V, D, and J genes are not shown for the TCRαβ sequences observed
only in the single-cell TCR sequencing data. Three TCRαβ sequences generated from single-cell TCR sequencing (nos. 2, 14, and 17) were also found to be
expressed by the DQ2.2-glut-L1–specific TCCs, which are mentioned in rightmost column. Two of the TCRαβ sequences (nos. 11 and 20) were observed
only by Sanger sequencing of DQ2.2-glut-L1–specific TCCs (last column) and not observed in TCR sequencing data of HLA-DQ2.2:DQ2.2-glut-L1 tetramer
sorted cells.
†By performing Sanger sequencing, we observed that TCC594.5.2.6 expresses single TCRα chain (TRAV9-2*01/TRAJ57*01). However, by performing single-cell
TCR sequencing, we were able to identify T cells that expressed an additional TCRα chain (TRAV27/TRAJ21).
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chain of Asn62 on the HLA-DQ2.2 α-chain, while Glu116β
formed a hydrogen bond with Asp66 on the HLA-DQ2.2 β-chain
(Fig. 2D). Trp111β of the CDR3β loop made additional vdw
contact with HLA-DQ2.2 α-chain at residues Phe58α, Thr61α, and
Val65α. Further vdw interactions were made between the Gly112β,
Gly113β, and Thr115β of the CDR3β loop and the HLA-DQ2.2
Fig. 1. Structures of TCR-HLA-DQ2.2:DQ2.2-glut-L1 ternary complexes. TCR 594 (A) and TCR 1005.2.56 (B). Footprint of the CDR loops of the TCR 594 (C) and TCR
1005.2.56 (D) on the HLA-DQ2.2:DQ2.2-glut-L1. CDR1α, CDR2α, and CDR3α are colored in red, pink, and purple, respectively, while the CDR1β, CDR2β, and CDR3β
are colored in green, light teal, and yellow, respectively. The TCR framework for each Vα- and Vβ-chain is colored orange and brown, respectively, for TCR 594, and
colored lime and deep-olive, respectively, for TCR 1005.2.56. The pie chart below show percentage of the CDR loops contributing to the buried surface area.
3066 | www.pnas.org/cgi/doi/10.1073/pnas.1914308117 Ting et al.
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β-chain including residues Asp66β, Thr61β, and Ile67β. Interest-
ingly, the positioning of the Trp111β in the CDR3β of the TCR 594
is analogous to that of the conserved Arg109 found in the CDR3β
loop of the HLA-DQ2.5:DQ2.5-glia-α2 reactive TCRs (SI Ap-
pendix, Fig. S1), making similar contact to HLA-DQ2.2 residues
Phe58α, Thr61α, and Asn62α, as well as gluten epitope residues at
position P5 and P7 (Fig. 2 C and D).
Gly109α and Thr112β from the TCR 1005.2.56 also interacted
with gluten epitope residues at position P5 (Fig. 3 D and E). How-
ever, the overall TCR:peptide interaction was further extended by
contacts between the germ-line–encoded CDR loops and the
DQ2.2-glut-L1 peptide residues P2-Phe, P3-Ser, P6-Glu, and P8-
Pro, including Tyr37α from the CDR1α loop, Gln57α from the
CDR2α loop, and Thr37α from the CDR1α loop (Fig. 3D). Notably,
the P7-Gln residue in the TCR1005.2.56:HLA-DQ2.2:DQ2.2-glut-
L1 ternary complex was orientated toward the antigen-binding
cleft and formed a hydrogen bond with Arg70β from HLA-
DQ2.2 (Fig. 3E) and was not involved in any direct TCR contact.
In TCR 594:HLA-DQ2.2:DQ2.2-glut-L1, Arg70β forms a salt
bridge with the Glu112α from the CDR3α loop and made polar
contacts with the P5-Gln of the DQ2.2-glut-L1 (Fig. 2D). In the
TCR1005.2.56:HLA-DQ2.2:DQ2.2-glut-L1 ternary complex,
however, the HLA-DQ2.2 residue Arg70β had rotated toward
the P7 peptide binding pocket, forming hydrogen bond with P7-Gln,
pulling it inwards, while making hydrogen bond with Thr112β and
Asp113β from the CDR3β loop of TCR 1005.2.56 (Fig. 3 D and E).
Overall, the TCR 1005.2.56 contacts with the HLA-DQ2.2:DQ2.
2-glut-L1 are more well distributed along the peptide compared
to TCR 594 whose interactions focused on the central region of
the peptide.
Comparison of HLA-DQ2.2:DQ2.2-glut-L1 and HLA-DQ2.5:DQ2.5-glia-α2.
The DQ2.2-glut-L1 peptide (PFSEQEQPV) used in this study was
derived from low molecular weight glutenin protein subsequent to
TG2 mediated deamidation of the P4 and P6 glutamine residues in
the native peptide sequence (PFSQQQQPV) to glutamate (14,
24). Crystal structures of HLA-DQ2.5:DQ2.5-glia-α1 and HLA-
DQ2.5:DQ2.5-glia-α2 reveal that lysine at position 71 of the
HLA-DQ2.5 β-chain is involved in binding of the P4-Glu and P6-
Glu (22, 23, 27). The electron density maps of the DQ2.2-glut-
L1 peptide recognized by TCR 594 (Fig. 4A) and TCR 1005.2.56
(Fig. 4B) were unambiguous. A more comprehensive hydrogen
bonding network is shown from the view of a TCR for these two
ternary complexes in Fig. 4 C and D, corresponding to P1 to P9
residues of the DQ2.2-glut-L1 peptide shown in Fig. 4 A and B.
Similar HLA-peptide contacts were observed in HLA-DQ2.2:DQ2.2-
glut-L1, where the P4-Glu and P6-Glu are buried deep into the
binding pockets, acting as anchor residues, interacting with Tyr9β,
Ser30β, and Lys71β of the HLA-DQ2.2 (Fig. 4 C and D).
Upon superposition, HLA-DQ2.2:DQ2.2-glut-L1 and HLA-
DQ2.5.DQ2.5-glia-α2 showed no major structural differences,
with an rmsd of 0.50 Å. In their membrane distal domains the
HLA-DQ2.2 and HLA-DQ2.5 have identical DQβ chains and
differ by 10 residues in their DQ α-chains (Fig. 4 E–G). None of
these polymorphic residues of HLA-DQ2.2 made direct contact
with the DQ2.2-glut-L1 epitope, or with the TCR in both of the
TCR 594:HLA-DQ2.2:DQ2.2-glut-L1 and TCR 1005.2.56:HLA-
DQ2.2:DQ2.2-glut-L1 complexes solved in this study (Fig. 4 E and
F). The only key polymorphic residue that is in contact with the
DQ2.2-glut-L1 peptide is the Phe/Tyr substitution in position 22 of
the DQ α-chain. Here, we clearly show that the presence of P3-Ser
in HLA-DQ2.2:DQ2.2-glut-L1 forms a hydrogen bond to side
chain of His24α and main chain of Tyr9α of the HLA-DQ2.2
molecule (Fig. 4 E and F). By contrast, in HLA-DQ2.5, Tyr22α hy-
drogen bonds with the His24α (Fig. 4G) (22, 23). Moreover, these
two HLA-DQ2.2:DQ2.2-glut-L1 complexes displayed relatively
conserved electrostatic-potential surfaces for TCR interaction
(Fig. 4 H and I). Hence, such selective P3-Ser peptide binding
preferences is attributed to a hydrogen-bonding network
whose functionality is differentially influenced by tyrosine and
Fig. 2. TCR 594 CDR loops in contact with the HLA-DQ2.2:DQ2.2-glut-L1. (A) The CDR1α and CDR2α loop contacting HLA-DQ2.2 β-chain. (B) The CDR2β
contacts with HLA-DQ2.2 α-chain. (C) CDR3α and CDR3β interactions with the DQ2.2-glut-L1 peptide. (D) Key interaction around the P5-Gln residue of the
DQ2.2-glut-L1 epitope.
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phenylalanine. While the polymorphic Phe22α is located at the
base of the HLA peptide binding cleft and has no direct contact
with the TCR, it provides a basis for understanding why P3-Ser
binds more favorably to HLA-DQ2.2 compared to HLA-DQ2.5.
These structural data are in keeping with a model previously
presented (14).
Role of P3-Ser as an Anchor in Peptide Binding to HLA-DQ2.2. To
further investigate the role of P3-ser as an anchor residue for
HLA-DQ2.2, we performed a competitive peptide binding assay
and compared the binding of DQ2.2-glut-L1 and 10 different P3-
Ser substituted peptide variants (SI Appendix, Table S6) to HLA-
DQ2.2 (Fig. 5). We contrasted the results with testing the same
peptides for binding to HLA-DQ2.5 (Fig. 5).
Among all of the 11 peptides with different amino acids at
P3 of the DQ2.2-glut-L1 epitope, the peptide containing P3-Ser
displayed the best binding to HLA-DQ2.2. Between the 10 P3-
Ser–substituted peptides, threonine substitution had the least
impact. The variant with cysteine also was a reasonable binder. A
possible explanation why threonine and cysteine could serve as
P3 anchors for HLA-DQ2.2 could be that their side chain can
establish the above-mentioned hydrogen bond to the side chain
of His24α and the main chain of Tyr9α. Further to this notion,
α-aminobutyric acid, which is structurally similar to serine except
for lacking the hydroxyl group, bound less well than the serine
variant. Notwithstanding, α-aminobutyric acid was better than
many of the other amino acids tested, indicating additional im-
portance of size and hydrophobicity for optimal anchoring into
the P3 pocket of HLA-DQ2.2. The patterns of binding of the 11
DQ2.2-glut-L1 variants to HLA-DQ2.5 was very different for
that of HLA-DQ2.2 with P3-Ser not being preferred. Taken to-
gether, the binding experiments substantiate the notion of P3-Ser
Fig. 3. TCR 1005.2.56 CDR loops in contact with the HLA-DQ2.2:DQ2.2-glut-L1. (A) The CDR1α, CDR2α, and CDR3α loops contact the HLA-DQ2.2 α-chain and
β-chain. The CDR1β, CDR2β (B), and CDR3β (C) interactions with the HLA-DQ2.2 α-chain and β-chain, respectively. (D) The CDR1α and CDR3β loops of the TCR
1005.2.56 that interacted the DQ2.2-glut-L1 peptide. The CDR3α, CDR1β, and CDR2β loop contacts with the peptide. (E) Key interaction around the P5-Gln and
P7-Gln residue of the DQ2.2-glut-L1 epitope.
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Fig. 4. Comparison of HLA-DQ2.2-glut-L1 and HLA-DQ2.5 in complexed with gluten epitopes. The DQ2.2-glut-L1 peptide is bound in the peptide-binding
groove, with carbon colored in salmon, nitrogen colored in blue, and oxygen colored in red. The TCR 594 (A) and TCR 1002.56 (B) docked on top of the HLA-
DQ2.2:DQ2.2-glut-L1 are shown as solid surface, and each of the TCR αβ pair were colored in brown/orange and green/lime, respectively. The peptide’s 2Fo-Fc
electron density map is shown in blue and contoured to 1 σ. Hydrogen bond interactions between HLA-DQ2.2 and the DQ2.2-glut-L1 epitope in the TCR
594:HLA-DQ2.2:DQ2.2-glut-L1 ternary complex (C) and in the TCR 1005.2.56:HLA-DQ2.2:DQ2.2.-glut-L1 ternary complex (D) are shown. Comparison of the
DQ2.2-glut-L1 peptide bound to HLA-DQ2.2 in the two ternary complexes solved showed minor movement in P7-Gln residues, highlighted in yellow circle.
Polymorphic residues on the ectodomain of HLA-DQ differing between HLA-DQ2.2 (E and F) and HLA-DQ2.5 (G) are represented in stick and colored in fire-
brick. The His24α interacts with P3-Ser in DQ2.2-glut-L1 (E and F) but with Tyr22α in HLA-DQ2.5 (G). The solvent-accessible electrostatic potential was cal-
culated for HLA-DQ2.2:DQ2.2-glut-L1 in complexed with TCR 594 (H) or TCR 1005.2.56 (I) and HLA-DQ2.5:DQ2.5-glia-α-2 (J). Electrostatic calculations were
performed using APBS (±5 kT/e).
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as a key anchor for peptide binding to HLA-DQ2.2 with the hy-
droxyl group of the serine side being functionally important.
TCR Affinity Measurements for the HLA-DQ2.2:DQ2.2-glut-L1 Complex.
As determined by surface plasmon resonance (SPR), the steady-
state affinity (KD) of the TCR 555, TCR 594, and TCR 1005.2.56
for the HLA-DQ2.2:DQ2.2-glut-L1 were 26.14 ± 2.64, 20.95 ±
4.06, and 22.17 ± 3.68 μM, respectively (Fig. 6). These values
corroborate previous T cell proliferation studies (14). None of these
TCRs tested showed any binding to HLA-DQ2.5:CLIP1 or HLA-
DQ2.2:DQ2.2-glia-α2, thereby highlighting the lack of cross-
reactivity of these TCRs.
To determine the extent of peptide sensitivity of these TCRs,
we generated three peptide mutants corresponding to the
solvent-exposed residues at position P2, P5, and P7 by replacing
them with an alanine. The impact of these substitutions was
measured by SPR. The PheP2Ala mutation reduced the affinity
by at least 10-fold (KD > 200 μM), whereas the GlnP5Ala mu-
tation abolished TCR binding to HLA-DQ2.2-glut-L1. This is
consistent with the crystal structure where P5-Gln played a
central role in mediating TCR 594 and TCR 1005.2.56 interac-
tion in HLA-DQ2.2:DQ2.2-glut-L1 (Figs. 2 C and D and 3 D and
E). The GlnP7Ala mutation abolished the binding of TCR 555
and TCR 594, whereas the TCR 1005.2.56 showed weak binding
(KD > 200 μM) to this mutant, suggesting a different mode of
interaction with this TCR. Indeed, as shown in the crystal
structure, the P7-Gln in the TCR1005.2.56:HLA-DQ2.2:DQ2.2-
glut-L1 ternary complex did not make any direct contact with the
TCR, contrary to the TCR594:HLA-DQ2.2:DQ2.2-glut-L1 ternary
complex (Fig. 3 D and E).
Discussion
HLA-DQ2.2 differs from HLA-DQ2.5 and HLA-DQ8 in gluten
peptide-binding preferences and CeD risk association. Immuno-
dominant gluten epitopes that binds stably to HLA-DQ2.5 were
found to bind unstably to HLA-DQ2.2 and, furthermore, did not
raise T cell responses in vivo in CeD patients carrying HLA-
DQ2.2 (14, 16). Rather T cell clones from CeD patients
expressing HLA-DQ2.2 recognized a unique set of gluten epi-
topes that commonly had a serine residue at position P3 (14, 16).
Here, we provide a molecular basis for the T cell-mediated response
to an HLA-DQ2.2–restricted immunodominant gluten epitope. We
show that, in contrast to HLA-DQ2.5– and HLA-DQ8–mediated
CeD, a diverse T cell repertoire underpins the response to HLA-
DQ2.2 presenting the glut-L1 epitope. Moreover, we provide a
structural basis underpinning this diverse TCR usage, by deter-
mining the crystal structures of two TCR:HLA-DQ2.2:DQ2.2-
glut-L1 complexes.
Several studies have provided insight into TCR recognition of
gluten epitopes presented by HLA-DQ2.5, HLA-DQ8, and
HLA-DQ8.5. For instance, the HLA-DQ8:DQ8-glia-α1 reactive
TCRs exhibit biased TRAV26-2/TRBV9-1 gene usage (18), and a
nongerm-line–encoded arginine residue in either the CDR3α or
CDR3β loop (23, 28). Moreover, TRAV20+/TRBV9+ TCRs re-
active with HLA-DQ8:DQ8-glia-α1 and HLA-DQ8:DQ8.5-glia-
γ1 also possessed a key arginine residue in their CDR1α loops
(28, 29). All TRAV26-1/TRBV7-2+ TCRs specific for DQ2.5-
glia-α2 had a nongerm-line–encoded arginine at position 109 of
the CDR3β loop, which forms key interactions with the P5-Leu
and P7-Tyr residues found within the gliadin epitopes (22). The
HLA-DQ2.5:DQ2.5-glia-α1 reactive TCRs also shows biased
TCR gene usage, TRAV4 and TRBV20-1 or TRBV29-1 (22, 30),
Fig. 5. Binding of unsubstituted and P3-susbstituted variants of the DQ2.2-glut-L1 epitope to HLA-DQ2.2 and HLA-DQ2.5. Synthetic peptides containing the
DQ2.2-glut-L1 epitope (Ac-QQPPFSEQEQPVLPQ, nine amino acid core sequence underlined), and variants substituted at P3 serine were tested as competitor
peptides. The inhibitory effect of the competitor peptides is shown as IC50 values. One 10-fold titration experiment and three 4-fold titration experiments
were performed. (A) Representative data showing results of one of the three fourfold titration experiments. (B) Results from all four independents exper-
iments depicted as relative binding capacities (i.e., compared to the unsubstituted DQ2.2-glut-L1 epitope). The relative binding values from each experiment
are shown as dots with bars representing mean values. A missing dot for some peptides is due to the titration curve not reaching its relevant IC50 value. Error
bars, SD.
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but they do not carry a conserved arginine that is essential for
recognition (31, 32). Ensuing structural studies have identified
specific structural features that provided a basis for the selec-
tion of biased TCR usage and the preferential usage of the Arg
residue (22, 23).
The TCR594:HLA-DQ2.2:DQ2.2-glut-L1 interactions resem-
bled some features of both TCR S2 and TCR S16 that recog-
nized HLA-DQ2.5:DQ2.5-glia-α1 and HLA-DQ2.5:DQ2.5-glia-α2,
respectively. Like the S2 TCR, the germ-line–encoded CDRs on
the TCR 594 Vα possesses a tyrosine that make similar interactions
with the HLA-DQ2 β-chain helix. Contrary to TCR S2, the TCR
594 interaction with the P5-Gln and P7-Gln was reminiscent of
TCR S16 and JR5.1 recognition of the HLA-DQ2.5:DQ2.5-glia-α2
epitope. Here, although the TCR594 did not possess a conserved
arginine residue within the CDR3β loop, Trp111β in the CDR3β
loop of the TCR 594 played an analogous role, forming extensive
interactions with the HLA-DQ2.2:DQ2.2-glut-L1 complex (SI
Appendix, Fig. S1). The nature of the contacts between the TCR
594 and the HLA-DQ2.2:DQ2.2-glut-L1 also provided a basis
for understanding the lack of cross-reactivity toward HLA-
DQ2.5:DQ2.5-glia-α2. Indeed, the HLA-DQ2.2:DQ2.2-glut-L1
reactive TCRs studied here appeared to be epitope-specific and
epitope-driven.
However, the TCR1005.2.56-HLA-DQ2.2-glut-L1 interactions
resembled TCR Bel502 and Bel602 that recognized HLA-DQ8-
glia-α1 and HLA-DQ8-glia-γ1, respectively (28, 29) (SI Appen-
dix, Fig. S2). Here, TCR Bel502 and Bel602 possess a conserved
Arg37 in the CDR1α loop that interacts with the backbone of the
gliadin peptide near the N termini. The TCR 1005.2.56, like
TCR 594, did not bear an arginine in the CDR3β loop nor in the
CDR1α loop. However, the Tyr37α in the CDR1α loop of the
TCR1005.2.56 sat atop of the N terminus of the DQ2.2-glut-L1
epitope in the same manner as the conserved Arg37α in the
CDR1α loop of TCR Bel502 and Bel602 (SI Appendix, Fig. S2B).
Despite HLA-DQ2.2 compensating for the substitution of
Tyr22α by selectively binding to gluten epitopes with P3-Ser, it
bears a lower risk of CD in comparison to HLA-DQ2.5. A higher
chance of proteolytic degradation and stricter binding require-
ments are likely what limits the repertoire of potential HLA-
DQ2.2 epitopes. In addition, the DQ2.2-glut-L1 has a chymo-
trypsin cleavage site between its P2 and P3 residues, making it
more susceptible to proteolytic degradation. The requirement of
the deamidation of glutamine residues at P4 and/or P6 for op-
timal binding to HLA-DQ2.2 further also limits the number of
candidate antigenic epitopes in gluten for individuals with this
allotype. These restrictions likely limit the bioavailability of
epitopes that could bind to HLA-DQ2.2.
In summary, we have investigated the structural basis of how
HLA-DQ2.2–restricted and CeD-derived TCRs bind to HLA-
DQ2.2 complexed with the immunodominant DQ2.2-glut-L1
epitope. The single polymorphic residue in HLA-DQ2.2 (Phe22α)
influences the hydrogen bond network within the peptide-binding
groove of HLA-DQ2.2 and selectively bind to gluten epitopes that
carry a P3-serine as anchor residue. What is remarkable is that
while the TCR-accessible features of the antigen-binding clefts of
HLA-DQ2.5 and HLA-DQ2.2 are very similar, the nature of the
bound epitopes generate markedly different responding TCR
repertoires. In HLA-DQ2.5–mediated CeD, the response is
characterized by biased TCR usage, while in HLA-DQ2.2–medi-
ated CeD, a diverse TCR response is generated. Thus, relatively
subtle differences in the peptide-centric atomic landscape can
have profound effects on the ensuing T cell response, which is
correlated with disease pathogenesis.
Methods
Patient Material. We characterized T cells isolated from gut biopsy-derived
T cell lines of four DQ2.2+ subjects that have been described previously
(14). According to the Oslo definitions of CeD and related terms (33), three
of these subjects (CD555, CD594, and CD627) fulfilled the criteria of CeD
while one subject (CD1005) fulfilled the criteria of potential CeD having
normal gut histology but highly positive anti-TG2 serology. The subjects
gave written informed consents for participation in the previous study, and
updated written informed consent forms were obtained for this study. The
responsible clinicians had access to sensitive patient data, whereas the
research was done on coded material. The study protocol was approved by
the Regional Ethical Committee (South East) for Medical and Health Re-
search Ethics (present project ID: 6544). From the T cell lines, we sorted
single T cells with HLA-DQ tetramers for TCR sequencing and TCRs of
already-established T cell clones were sequenced (TCC627.1.3.199,
TCC594.5.2.6, and TCC555A.1.4.38 from ref. 14 and TCC1005.2.54, TCC1005.2.56,
TCC1005.2.57, TCC1005.2.58, TCC1005.2.60, TCC1005.2.62, and TCC1005.2.65
from ref. 34).
Fig. 6. Affinity measurement of TCR 555, 594, and 1005.2.56. Affinity for HLA-DQ2.2:DQ2.2-glut-L1 WT and the P2-Ala, P5-Ala, and P-7Ala epitope mutants
were measure via SPR. Two to four independent experiments (with the number of replicates shown as n numbers) were carried out for each of the TCR
against each of HLA-DQ2.2-glut-L1 WT and epitope mutants. Binding curve showed represent an independent experiment of TCR 555, TCR 594, TCR 1005.2.56
(labeled as TCR256) binding to HLA-DQ2.2:DQ2.2-glut-L1. All data were combined for each TCR and a one-site specific-binding model was used for curve
fitting. HLA-DQ2.5-CLIP was used as negative control and acted as baseline reference value. Error bars, SD. NB, no binding.
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Tetramer Staining, Surface Antibody Staining, and Fluorescence-Activated Cell
Sorting. Tetramers of recombinant HLA-DQ2.2 covalently linked with DQ2.2-
glut-L1 peptide (QPPFSEQEQPVL, underlined 9-mer core amino acid se-
quence) and CLIP1 (PVSKMRMATPLLMQA, negative control for nonspecific
binding) were produced as per Dorum et al. (24) and conjugated with
phycoerythrin (PE)-labeled streptavidin (Invitrogen) and allophycocyanin
(APC)-labeled streptavidin (ProZyme), respectively. Cryopreserved T cell
lines were thawed and stained with PE-conjugated HLA-DQ2.2:DQ2.2-glut-
L1 (10 μg/mL) and APC-conjugated HLA-DQ2.2: CLIP1 (10 μg/mL) for 2 h at
37 °C. Following tetramer staining, the cells were stained with the mix of
surface antibodies for fluorescence-activated cell sorting (FACS). We sorted
live singlets that were CD3+, CD8−, CD4+, HLA-DQ2.2:DQ2.2-glut-L1 tet-
ramer+, and HLA-DQ2.2:CLIP1 tetramer− (SI Appendix, Fig. S3). The cells
were sorted in 96-well plate containing lysis buffer for single-cell TCR se-
quencing. The sorting was performed with a FACS Aria II instrument (BD
Biosciences) at the Flow Cytometry Core Facility (Oslo University Hospital),
and the flow cytometry data were analyzed with FlowJo software (FlowJo
LLC). The following antibodies were used in the study: CD3-Superbright 600
(eBioscience), CD4-APC-H7 (BD Biosciences), and CD8-PerCP (eBioscience).
LIVE/DEAD marker fixable violet stain (Thermo Fischer Invitrogen) was used
to exclude dead cells.
TCR Sequencing of T Cell Clones. Sequences of rearranged TCR-α and TCR-β
genes of T cell clones were obtained by Sanger sequencing using a protocol
as described (35).
Single-Cell TCR Gene Sequencing and Processing of TCR Gene Sequences. We
used a previously published protocol, based on nested PCR amplification
using multiplex TRAV and TRBV primers, for single-cell TCRαβ sequencing (3,
36). The processing of the raw sequences generated from Illumina NGS was
carried out as described (3). Sequencing was performed using Illumina MiSeq
(250 bp PE) platform at the Norwegian Sequencing Centre (Oslo University
Hospital).
Competitive Peptide Binding Assays. The competitive peptide binding assay
was performed as described previously (14, 37). In brief, the Epstein–Barr
virus (EBV)-transformed B-cell lines VAVY (#9023) and MOU (#9050) were
used as the source of HLA-DQ2.5 and HLA-DQ2.2 molecules. Microtiter
plates (96 well, Nunc) were coated with an anti-DQ mAb (mAb and SPV-L3;
2 μg per well) as capture antibody for overnight at 4 °C. The wells were then
blocked with phosphate buffered saline/gelatin (0.2%) at 37 °C for 5 h. The
plates were washed, and cell lysate of EBV cells (equivalent of 4 million cells)
was added to wells and incubated at 4 °C overnight. The plates were washed
and biotinylated indicator peptide P418 (EPRAPWIEQEGPEYW-biotin, 0.5 μM)
together with unlabeled competitor peptides (GL Biochem) were added in bind-
ing buffer with protease inhibitors (Complete ethylenediaminetetraacetic acid
[EDTA]-free tablets, Roche Molecular Biochemicals) and 1 mM dithiothreitol
followed by 48-h incubation at 37 °C. The plates were washed and incubated
with streptavidin-europium diluted (1000× dilution) in DELFIA assay buffer
(Wallac) for 45 min at room temperature. The plates were washed and in-
cubated with DELFIA enhancement solution (Wallac) for 15 min at room
temperature. Binding of the indicator peptide was then measured as Eu
counts in a time-resolved fluorometer (Wallac 1420 multilabel counter). IC50
values (the concentration of the competitor peptide required for half-
maximal inhibition of the binding of the indicator peptide) were estab-
lished for each peptide. One 10-fold titration experiment and three 4-fold
titration experiments were performed. The relative binding capacity was cal-
culated as the ratio of the IC50 value of the DQ2.2-glut-L1 to the IC50 value of
the P3-substituted peptide variants.
Protein Expression and Purification. cDNAs (Genscript) encoding the individual
extracellular domains of TCRα-chain and β-chain, with an engineered in-
terchain disulfide linkage in the constant domains, were cloned into the pET-
30 vector and expressed in Escherichia coli BL21DE3. The TCR proteins were
purified from inclusion bodies, as described previously (38, 39). The TCR αβ
heterodimers were refolded in the presence of 5 M Urea, followed by di-
alysis and further purification through anion exchange chromatography,
size-exclusion chromatography, and hydrophobic-interaction chromatogra-
phy as described previously (18).
For SPR and structural experiments, the extracellular domains of the HLA-
DQ2.2 α-chain and HLA-DQ2.2-glut-L1 β-chain (with glut-L1 epitope co-
valently linked to the HLA-DQ2.2 β-chain) were coexpressed as soluble
protein in High Five insect cells (Trichoplusia ni BTI-TN-5B1-4 cells; Invi-
trogen), via a baculovirus expression system as described previously (17).
Briefly, baculovirus HLA-DQ2.2 expression constructs had enterokinase-
cleavable Fos and Jun zippers at the C-terminal ends of the α-chain and
β-chain, respectively, to promote dimerization. The C terminus of the β-chain
also included a BirA recognition sequence for biotinylation as described
previously (18), as well as a histidine tag for purification using immobilized
metal ion affinity chromatography. Before crystallization, the Fos and Jun
zippers were removed by enterokinase (Genscript) digestion, followed by
separation using anion exchange chromatography (HiTrap Q HP, GE
Healthcare). Purified HLA-DQ2.2:DQ2.2-glut-L1 was mixed in a 1:1 ratio with
purified TCR 594 or TCR 1005.2.56, and the protein complex was then pu-
rified by size exclusion chromatography (Superdex 200; GE Healthcare).
Three HLA-DQ2.2-glut-L1 epitope mutants were generated by replacing the
glut-L1 WT core sequence (PFSEQEQPV) with glut-L1-P2Δ (PASEQEQPV),
glut-L1-P5Δ (PFSEAEQPV), and glut-L1-P7Δ (PFSEQEAPV) separately in the
HLA-DQ2.2 β-chain and coexpressed with HLA-DQ2.2 α-chain via a baculo-
virus expression system as described above.
Crystallization, Data Collection, and Processing. The TCR 594/TCR 1005.2.56
and the HLA-DQ2.2:DQ2.2-glut-L1 complex, in 10 mM Tris (pH 8), 150 mM
NaCl, were concentrated to 6mg/mL. Crystallization was carried out using the
hanging drop vapor diffusionmethod at 17 °C. For TCR594:HLADQ2.2:DQ2.2-
glut-L1, diffraction quality crystal was obtained in conditions 0.1 M 2-(N-
morpholino)ethanesulfonic acid pH 6.5, 5% vol/vol MPD, and 15% wt/vol
PEG6K, and crystallization droplets were set up by adding 1 μL of the mother
liquor to 1 μL of protein solution. Crystals typically appeared within 2–7 d.
For TCR1005.2.56:HLA-DQ2.2:DQ2.2-glut-L1, diffraction quality crystal was
obtained in an optimized Morpheus screen conditions 0.1 M Mops/Hepes pH
7.5, 12.5% vol/vol PEG1K, 12.5% vol/vol MPD, 12.5% wt/vol PEG 3350, and
0.04 M nitrate phosphate sulfate mixture (40), and crystallization droplets
were set up by adding 1 μL of the mother liquor to 1 μL of protein solution
and with the addition of 0.2 μL of seed stock. Crystals typically appeared within
2–3 wk. Protein crystals were exposed to cryoprotectant, 20% glycerol for 30 s
before being flash-cooled in liquid nitrogen. Datasets were collected on the
MX2 beamline of the Australian Synchrotron. Data were integrated with XDS
and scaled and merged in Aimless. Phases were obtained using molecular re-
placement in PhaserMR, CCP4suite (41). Protein Data Bank (PDB) ID code 4OZH
(chain A and B, without glycans or peptides for HLA; chain G and H for TCR) was
used as search model for HLA-DQ2.2:DQ2.2-glut-L1 and TCR 594 for molecular
replacement. The data collected for the TCR594:HLADQ2.2:DQ2.2-glut-L1was
highly anisotropic, thus ellipsoidal truncations and anisotropic scaling were
carried out at the Diffraction Anisotropic Server (42). The structure was built
and refined in Coot and PHENIX (43, 44). Final model was validated in
Molprobity (44).
Surface Plasmon Resonance Measurement and Analysis. Surface plasmon res-
onance experiments were conducted on a BIAcore T200 system (GE
Healthcare Life Sciences) instrument using HBS buffer (10 mM Hepes-HCl, pH
7.4, 150 mM NaCl, and 0.005% surfactant P20). The biotinylated HLA-
DQ2.5:CLIP2, HLA-DQ2.2:DQ2.2-glut-L1, and respective peptide mutant
DQ2.2-glut-L1-P2Δ, DQ2.2-glut-L1-P5Δ, DQ2.2-glut-L1-P7Δ were immobi-
lized on a streptavidin-coated Biacore Series S Sensor Chip SA (SA Chip; GE
Healthcare Life Sciences), creating a surface density of ∼800–1,000 response
units (RU). The TCR 555, TCR 594, and TCR 1005.2.56 (one in two serial di-
lutions from the maximum concentration of 200 μM) were injected over the
chip at 10 μL/min for 2 min. The TCR response to HLA-DQ2.5:CLIP2 alone was
subtracted from the response to HLA-DQ2.2:DQ2.2-glut-L1 and respective
epitope mutants. Data in the main text are representative of two or four
independent experiments. The equilibrium dissociation constant, KD, was
generated with nonlinear regression analysis of the combined data using
Prism (GraphPad Software).
Data Availability. The protein structural data that support the findings of this
study have been deposited in the RCSB PDB with the ID codes 6PX6
and 6PY2. All of the single-cell TCR sequencing raw data generated in
this study are available in the European Genome-phenome Archive
(EGAS00001003673).
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